Renalytix (LON:RENX) Trading Down 10% – Time to Sell?

Renalytix Plc (LON:RENX) was down 10% on Tuesday . The stock traded as low as GBX 1.60 and last traded at GBX 1.80. Approximately 8,739 shares traded hands during trading, a decline of 99% from the average daily volume of 1,059,987 shares. The stock had previously closed at GBX 2.

Renalytix Stock Down 20.0%

The company has a market capitalization of £6.99 million, a PE ratio of -0.40 and a beta of 1.97. The company has a debt-to-equity ratio of -118.57, a current ratio of 1.21 and a quick ratio of 2.42. The company has a 50-day moving average of GBX 2.54 and a two-hundred day moving average of GBX 5.07.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).